XYOSTED Feedback......

Expect layoffs and TRx and NRx decline.

 

The competition is concerned with share erosion to Xyosted.

 

Nice job Antares!

Latest weekly data Xyosted New RX 91 vs Teva's Testosterone Enanthate New Rx 83.

Not bad at all. We are just one month into launch during a time of holidays and vacations with docs and patients busy and Xyosted already surpassed one competitor!

We should see Xyosted become the top prescribed testosterone treatment because it really is the best in class.

Congratulations!

 

186 new prescriptions for Xyosted this week! Nice job.

 

You are a fool. Best in class product and we are exceeding coverage expectations through Q1. The first 6 months is always tough but things are going.

 

225 total RX and new RX- 215 for Xyosted in the latest week! Docs do love it early on in the launch.

 

its all based on managed care no matter how good or great your product is people will not pay out of their own pocket when the have other options that are significantly less expensive

 

#truth
With this and the lack of availability of Epi for Teva, I see things going south.

 

Actually Teva reported recently that the shortage of epinephrine will soon abate. By the second quarter they should be no shortage issues. Furthermore Teva expects to have 50% of the Epi market by the end of 2019. Things are looking up.

 

Didn’t Teva also “expect” to launch officially last year? Looks like they couldn’t meet that expectation, entirely. Also, expectations are just that, expectations. I would expect patients will not foot the bill for Testosterone if there are cheaper (without black box warnings) alternatives available. #truth #settingunmetexpectations

 

Here is a raised target price for ATRS. You guys seem to be in a very good position!


"Antares Pharma upside share target raised to $18-$20 at Jefferies Jefferies analyst Anthony Petrone's revised sum-of-the-parts analysis on Antares Pharma continues to assign a current risk-adjusted value of $8 per share. However, it now sees upside to $18-$20, versus $15 prior, based on "strong initial feedback" on Xyosted, "longer tailwind" for Makena, larger opportunity for generic EpiPen given ongoing shortages, and earlier potential launch of generic Forteo. Early feedback from physicians and patients is positive and continues to support that 20% share capture is feasible for Xyosted over time, Petrone tells investors in a research note. He keeps a Buy rating on Antares Pharma."

 

Nice pop today. Over 10% gain in ATRS!

The company will also hold the 4th quarter and full year 2018 webcast this Thursday February 28th at 8:30AM. This is great news since typically the year end conference is held in March. The information is in the link below.



Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

 

Tomorrow is D Day for Antares. The stock has been hot every day this week in anticipation of tomorrow's call. With good news as expected shares may break 4. We will see.

 

ATRS very hot stock this week Up 15% not shabby. The company will be profitable soon and has great products.

 

Antares seems way too sneaky for my money...looks like someone high up on the inside (previous employee) is calling them out with their lackadaisical response to the “one suicide” during clinical trials. LIARS!! Not to be trusted! Also, I’m not certain all of their “claims” are truthful. Someone should really dig in to the stability of the drug.....like FDA!

http://securities.stanford.edu/filings-documents/1063/API00_20/2018109_r01c_17CV08945.pdf

 

Anyone can sue anyone in the good all USA.

Keep in mind that suicide can be as a result of depression. All testosterone products are associated with depression. The good thing about Xyosted is that the highs and lows associated with testosterone therapy is much less in between doses. The other products have higher peaks and lower valleys possible exaggerating the intensity of depression. Therefore Xyosted may be the testosterone product that has less mood swings that may lead to depression and suicide.

Finally suicide occurs due to a multitude of factors and finding the source in many cases is virtually impossible.

A few individuals are short the stock betting the price will fall but the price had a big rise this week and they are hurting and losing a lot of money. You will see negative articles and comments by those individuals to bring share price down but it won't work. The company will shortly make a profit and a well know stock analyst has a 20 dollar target on shares of ATRS.

 

"Someone should really dig in to the stability of the drug" --- Why? What proof do you provide? The drug has been proven more successful than IM injection and topical applications.

You sound like a paid astroturfer.

 

I do not compromise my ethics, and would not mention the stability of the drug if it were not true. The drug may, in fact, be more successful than IM/topical applications, but it won’t last for the claimed shelf life.

 

So at first you discussed the suicide reported in one patient in the drug study. Now it is a stability issue. Please get your fake reasons why this won't fly. It is going gangbusters but some won't benefits as Xyosted becomes the market leader. I can't wait for the next bs manufactured report you can come up with. Be a little creative please.

 

My original post included the stability issue. Perhaps if you did more digging you may discover some “creativity” from your co-workers hiding the same stability issue with which I speak of.